Mesquite Print House

Biotech 2009 — Life Savoir: Navigating the Sea Change

The 23rd annual survey on the biotech industry, Biotech 2009 — Life Savoir: Navigating the Sea Transformation, has just recently been released. This kind of report signifies that the biotech industry had a profit-making year in 2008, although it had been overshadowed by recent events. In this article, we will examine some of the challenges confronted by this market and consider possible structural alterations. We’ll contemplate possible new rules and institutional agreements to improve future.

The public value markets have never been create to deal with the problems of enterprises engaged in R&D-only activities. Biotech businesses cannot be appreciated based on their very own earnings — most have no earnings — because their very own value is dependent upon ongoing R&D projects. For that reason, investors contain little knowledge of biotech companies’ financial effectiveness and are not able to accurately judge their long term worth based on a famous record. Additionally , there are no standards for reporting intangible resources and valuing unfunded R&D projects.

Even though biotech businesses performed very well during the COVID-19 pandemic, they experienced challenges in access to capital and valuations. A current report simply by Ernst & Young LLP provides an kept up to date snapshot on the industry as well as future potentials. The article shows that the industry’s near future revenues and R&D investment opportunities look good, despite the going down hill macroeconomic circumstances. The survey also reveals a large tide of cash waiting to be invested in future biotech products.

Scroll to Top